398 related articles for article (PubMed ID: 28301264)
1. Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.
Dess RT; Sun Y; Matuszak MM; Sun G; Soni PD; Bazzi L; Murthy VL; Hearn JWD; Kong FM; Kalemkerian GP; Hayman JA; Ten Haken RK; Lawrence TS; Schipper MJ; Jolly S
J Clin Oncol; 2017 May; 35(13):1395-1402. PubMed ID: 28301264
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
Wang K; Eblan MJ; Deal AM; Lipner M; Zagar TM; Wang Y; Mavroidis P; Lee CB; Jensen BC; Rosenman JG; Socinski MA; Stinchcombe TE; Marks LB
J Clin Oncol; 2017 May; 35(13):1387-1394. PubMed ID: 28113017
[TBL] [Abstract][Full Text] [Related]
3. Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer.
Atkins KM; Rawal B; Chaunzwa TL; Lamba N; Bitterman DS; Williams CL; Kozono DE; Baldini EH; Chen AB; Nguyen PL; D'Amico AV; Nohria A; Hoffmann U; Aerts HJWL; Mak RH
J Am Coll Cardiol; 2019 Jun; 73(23):2976-2987. PubMed ID: 31196455
[TBL] [Abstract][Full Text] [Related]
4. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer.
Wang K; Pearlstein KA; Patchett ND; Deal AM; Mavroidis P; Jensen BC; Lipner MB; Zagar TM; Wang Y; Lee CB; Eblan MJ; Rosenman JG; Socinski MA; Stinchcombe TE; Marks LB
Radiother Oncol; 2017 Nov; 125(2):293-300. PubMed ID: 29050957
[TBL] [Abstract][Full Text] [Related]
5. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
Singh AK; Lockett MA; Bradley JD
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
[TBL] [Abstract][Full Text] [Related]
6. Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer.
Contreras JA; Lin AJ; Weiner A; Speirs C; Samson P; Mullen D; Campian J; Bradley J; Roach M; Robinson C
Radiother Oncol; 2018 Sep; 128(3):498-504. PubMed ID: 29859754
[TBL] [Abstract][Full Text] [Related]
7. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer.
Amini A; Yang J; Williamson R; McBurney ML; Erasmus J; Allen PK; Karhade M; Komaki R; Liao Z; Gomez D; Cox J; Dong L; Welsh J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e391-8. PubMed ID: 22284035
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
[TBL] [Abstract][Full Text] [Related]
9. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
[TBL] [Abstract][Full Text] [Related]
10. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
[TBL] [Abstract][Full Text] [Related]
11. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
[TBL] [Abstract][Full Text] [Related]
12. [Relationship of dose-volume histogram parameters and computed tomography grading of radiation-induced lung injury in patients with non-small cell lung cancer treated by three-dimensional conformal radiotherapy].
Xing J; Li JB; Yu JM; Lu J; Xu M; Fan TY; Shao Q; Guo SF
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):676-81. PubMed ID: 19173909
[TBL] [Abstract][Full Text] [Related]
13. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
14. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
[TBL] [Abstract][Full Text] [Related]
15. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
Werner-Wasik M; Xiao Y; Pequignot E; Curran WJ; Hauck W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):56-61. PubMed ID: 11516851
[TBL] [Abstract][Full Text] [Related]
16. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
[TBL] [Abstract][Full Text] [Related]
17. Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer.
Kumar S; Feddock J; Li X; Shearer AJ; Hall L; Shelton BJ; Arnold S; McGarry RC
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):652-659. PubMed ID: 29280459
[TBL] [Abstract][Full Text] [Related]
18. Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy.
Sonnick MA; Oro F; Yan B; Desai A; Wu AJ; Shi W; Zhang Z; Gelblum DY; Paik PK; Yorke ED; Rosenzweig KE; Chaft JE; Rimner A
Clin Lung Cancer; 2018 Jan; 19(1):e131-e140. PubMed ID: 28756051
[TBL] [Abstract][Full Text] [Related]
19. Mean Heart Dose Is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiation Therapy.
Atkins KM; Bitterman DS; Chaunzwa TL; Kozono DE; Baldini EH; Aerts HJWL; Tamarappoo BK; Hoffmann U; Nohria A; Mak RH
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1473-1479. PubMed ID: 33713743
[TBL] [Abstract][Full Text] [Related]
20. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
